Correlation of age and severity of clinical manifestation assessed by UPDRS in patients with idiopathic Parkinson's disease.

Medical Archives 01/2014; 68(1):44-6. DOI: 10.5455/medarh.2014.68.44-46
Source: PubMed

ABSTRACT In older people with Parkinson's disease the symptoms are more expressed. Background: Essential change in Parkinson's disease is the impaired neurotransmission in basal ganglia. Idiopathic Parkinson's disease (IPD) is the most frequent type of Parkinsonism, being present in about 70% of the patients with Parkinsonism.
This study has been prospective, clinically one, which has been lasting for whole 2 years. This study comprised a total of 32 subjects with clinically verified diagnosis for idiopathic Parkinson's disease, 18 men and 14 women (with mean age of 52,7 years). Control group consisted of 31 randomly selected, literally healthy persons, at similar age, with similar gender representation without clinical and anamnestic data for Parkinsonism and similar clinical entities. This study was made at the University Clinic of Neurology in Skopje, Medical Faculty, University "St. Cyril and Methodius'. The persons investigated had idiopathic Parkinson's disease (IPD), in whom IPD was verified by means of: detailed anamnesis, detailed clinical neurologic examination, strictly keeping to Brain Bank Criteria, and by means of neurophysiologic investigations, neuroimaging investigations and neuropsychologic investigations. Minimal symptoms of IPD after UPDRS were present in 34.4% of the examinees, there were 40.6% with slight signs, while equal number of the examinees 4 (12.5%) had pronounce and very expressed symptoms of Parkinson's disease after UPDRS.
Parkinson's disease is with more expressed signs and symptoms and with slight symptoms in older patients with this diagnosis.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The impact of Parkinson's disease on quality of life may vary depending on age at onset. We investigated the effect of age at onset on quality of life in a large Parkinson's disease population (n = 426) using a disease-specific rating scale (PDQ-39) and with careful adjustment for confounding and intermediary factors. We also explored the relationship between depression and excessive daytime sleepiness by age at onset and compared this with the general population. We found that a younger age at onset was significantly associated with worse overall quality of life scores (odds ratio, 2.66; 95% confidence interval, 1.39-5.09; P = .003), but this was attenuated by adjustment for depression as an intermediary factor (odds ratio, 1.86; 95% confidence interval, 0.84-4.11; P = .13). Younger onset was also a risk factor for poor emotional well-being independent of depression status. Risk of depression and excessive daytime sleepiness were elevated in patients with Parkinson's disease compared with controls (odds ratio, 2.99; 95% confidence interval, 1.93-4.65; P < .001; and odds ratio, 3.84; 95% confidence interval, 2.56-5.75; P < .001, respectively), with similar findings seen in both early- and late-onset groups. Our study highlights the need for accurate diagnosis and treatment of depression in younger-onset patients in order to improve quality of life.
    Movement Disorders 09/2011; 26(11):2011-8. DOI:10.1002/mds.23763 · 5.63 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The motor signs of Parkinson's disease are thought to result in large part from a reduction of the level of dopamine in the basal ganglia. Over the last few years, many of the functional and anatomical consequences of dopamine loss in these structures have been identified, both in the basal ganglia and in related areas in thalamus and cortex. This knowledge has contributed significantly to our understanding of the link between the degeneration of dopamine neurons in the midbrain and the development of parkinsonism. This review discusses the evidence that implicates electrophysiologic changes (including altered discharge rates, increased incidence of burst firing, interneuronal synchrony, oscillatory activity, and altered sensorimotor processing) in basal ganglia, thalamus, and cortex, in parkinsonism. From these studies, parkinsonism emerges as a complex network disorder, in which abnormal activity in groups of neurons in the basal ganglia strongly affects the excitability, oscillatory activity, synchrony and sensory responses of areas of the cerebral cortex that are involved in the planning and execution of movement, as well as in executive, limbic or sensory functions. Detailed knowledge of these changes will help us to develop more effective and specific symptomatic treatments for patients with Parkinson's disease.
    Clinical Neurophysiology 08/2008; 119(7):1459-74. DOI:10.1016/j.clinph.2008.03.017 · 2.98 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The risk of developing levodopa-associated dyskinesia is known to vary inversely with the age of Parkinson's disease onset. This study quantifies dyskinesia risks for different Parkinson's onset ages in a patient population treated at the Parkinson's Disease Research, Education, and Clinical Center at the San Francisco Veterans Affairs Medical Center. Medical records were reviewed to determine age of Parkinson's onset, medication history, and dyskinesia onset. Dyskinesia risks were determined by using Kaplan-Meier analysis. Cox proportional hazard models were used to compare age groups and to perform multivariate modeling. This study included 109 patients with Parkinson's, 105 of whom had onset of symptoms after 1989. At 5 years of levodopa treatment, the dyskinesia risk for patients with onset age 40-49 was 70%, decreasing to 42% for onset ages 50-59, 33% for onset ages 60-69, and 24% for onset ages 70-79. Pairwise comparisons between the 40-49 age group and the other age groups were statistically significant in time-to-event models. After 5 years of levodopa treatment, dyskinesia risks became uniformly high regardless of age of onset. These results suggest it is appropriate to use different baseline dyskinesia risks in clinical decision-making for patients on the basis of their ages of onset. However, the most significant difference occurs between ages 40-49 and ages 50-79, and if more than 5 years of levodopa therapy are anticipated, dyskinesia risk may have less utility when deciding upon Parkinson's therapy. Drug studies for Parkinson's disease should also take age of Parkinson's onset into account when analyzing dyskinesia outcomes.
    Movement Disorders 07/2010; 25(9):1177-82. DOI:10.1002/mds.23068 · 5.63 Impact Factor

Full-text (2 Sources)

1 Download
Available from
Jan 20, 2015